Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker

Background: Elevated plasmatic lactate dehydrogenase (LDH) levels are associated with worse prognosis in various malignancies, including metastatic breast cancer (MBC). Nevertheless, no data are available on the prognostic role of LDH as a dynamic biomarker during first-line treatment in unselected...

Descripción completa

Detalles Bibliográficos
Autores principales: Pelizzari, Giacomo, Basile, Debora, Zago, Silvia, Lisanti, Camilla, Bartoletti, Michele, Bortot, Lucia, Vitale, Maria Grazia, Fanotto, Valentina, Barban, Serena, Cinausero, Marika, Bonotto, Marta, Gerratana, Lorenzo, Mansutti, Mauro, Curcio, Francesco, Fasola, Gianpiero, Minisini, Alessandro Marco, Puglisi, Fabio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770929/
https://www.ncbi.nlm.nih.gov/pubmed/31450641
http://dx.doi.org/10.3390/cancers11091243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6770929/
https://www.ncbi.nlm.nih.gov/pubmed/31450641
http://dx.doi.org/10.3390/cancers11091243

Ejemplares similares